Assessment

melphalanflufenamide

Multiple myeloma in adults who have received at least 3 prior lines of therapy, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one monoclonal CD38 antibody, and who have shown disease progression during or after the last therapy